Skip to content

Debt-to-assets at other companies

Eli Lilly logo
Eli LillyLLY
0.4×-0.1×
Amgen logo
AmgenAMGN
0.6×0.0×
Viking Therapeutics logo
Viking TherapeuticsVKTX
0.0×
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
0.0×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
2.4×+2.4×
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
0.1×0.0×

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.3B+475%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Calculated from MBX Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s debt-to-assets?
MBX Biosciences, Inc. (MBX) reported debt-to-assets of 0× in Q1 2026.
How has MBX Biosciences, Inc.'s debt-to-assets changed year-over-year?
MBX Biosciences, Inc.'s debt-to-assets increased by 140.0% year-over-year, from 0× to 0×.
What is the long-term trend for MBX Biosciences, Inc.'s debt-to-assets?
Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s debt-to-assets has grown at a -37.2% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.